UA110505C2 - Імуногенні композиції bordetella bronchiseptica - Google Patents

Імуногенні композиції bordetella bronchiseptica

Info

Publication number
UA110505C2
UA110505C2 UAA201309553A UAA201309553A UA110505C2 UA 110505 C2 UA110505 C2 UA 110505C2 UA A201309553 A UAA201309553 A UA A201309553A UA A201309553 A UAA201309553 A UA A201309553A UA 110505 C2 UA110505 C2 UA 110505C2
Authority
UA
Ukraine
Prior art keywords
canine
immunogenic composition
bordetella bronchiseptica
composition containing
vinakhid
Prior art date
Application number
UAA201309553A
Other languages
English (en)
Inventor
Omar Yousif Abdelmagid
Josef Michael Bricker
Shelly Lynn Shields
Jeffrey E Galvin
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of UA110505C2 publication Critical patent/UA110505C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід належить до імуногенної композиції, що містить Bordetella bronchiseptica та виділений антиген пертактину р68. Також вакцина може додатково містити антигени вірусу собачого парагрипу (CPIV), собачого аденовірусу серотипу 2 (CAV-2), собачого респіраторного коронавірусу собак (CRCoV) та Mycoplazma cynis. Винахід також належить до застосування заявленої композиції для лікування та запобіганні виникненню респіраторних інфекцій у собак.
UAA201309553A 2011-02-04 2012-03-02 Імуногенні композиції bordetella bronchiseptica UA110505C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161439597P 2011-02-04 2011-02-04
PCT/IB2012/050512 WO2012104821A1 (en) 2011-02-04 2012-02-03 Immunogenic bordetella bronchiseptica compositions

Publications (1)

Publication Number Publication Date
UA110505C2 true UA110505C2 (ru) 2016-01-12

Family

ID=45755432

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201309553A UA110505C2 (ru) 2011-02-04 2012-03-02 Імуногенні композиції bordetella bronchiseptica
UAA201309552A UA110504C2 (ru) 2011-02-04 2012-03-02 Композиції для комплексу респіраторних захворювань собак

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201309552A UA110504C2 (ru) 2011-02-04 2012-03-02 Композиції для комплексу респіраторних захворювань собак

Country Status (27)

Country Link
US (1) US20130302369A1 (ru)
EP (2) EP3858381A1 (ru)
JP (1) JP5833145B2 (ru)
KR (1) KR101647180B1 (ru)
CN (2) CN107296955B (ru)
AU (2) AU2012213035A1 (ru)
BR (1) BR112013019675B8 (ru)
CA (1) CA2826060C (ru)
CL (1) CL2013002219A1 (ru)
CO (1) CO6791568A2 (ru)
CY (1) CY1124093T1 (ru)
DK (1) DK2670432T3 (ru)
ES (1) ES2869175T3 (ru)
HR (1) HRP20210575T1 (ru)
HU (1) HUE055669T2 (ru)
LT (1) LT2670432T (ru)
MX (1) MX347177B (ru)
PH (1) PH12013501598B1 (ru)
PL (1) PL2670432T3 (ru)
PT (1) PT2670432T (ru)
RS (1) RS61723B1 (ru)
RU (1) RU2554480C2 (ru)
SI (1) SI2670432T1 (ru)
SM (1) SMT202100233T1 (ru)
UA (2) UA110505C2 (ru)
WO (1) WO2012104821A1 (ru)
ZA (1) ZA201306615B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2750683T4 (da) 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
EP2854847B1 (en) * 2012-05-31 2019-08-07 Zoetis Services LLC Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
UA130246C2 (uk) * 2013-09-19 2025-12-31 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
EP4241853B1 (en) * 2013-11-26 2026-02-11 Zoetis Services LLC Compositions for induction of immune response
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases
WO2025170904A1 (en) * 2024-02-07 2025-08-14 Zoetis Services Llc Injectable vaccines against canine respiratory diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571618A1 (fr) 1984-10-12 1986-04-18 Virbac Ctre Rech Biolog Nouveau vaccin contre la tracheobronchite infectieuse canine et son procede de preparation
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
DE69736709T2 (de) * 1996-07-02 2007-10-04 Sanofi Pasteur Ltd., Toronto Vielwertige dtp-polio-impfstoffe
DK1284993T3 (da) * 2000-05-25 2008-07-28 Pasteur Institut Polypeptider der indeholder polymorfier af repeat-regionerne i pertactin fra bordetella pertussis, bordetella parapertussis og bordetella bronchiseptica, anvendelse deraf i diagnostik og i immunogene præparater
GB0217434D0 (en) * 2002-07-27 2002-09-04 Royal Vetinary College Biological material
MXPA05008051A (es) * 2003-01-29 2005-09-21 Pfizer Prod Inc Vacunas caninas contra bordetella bronchiseptica.
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
EP1667712B1 (en) * 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
WO2006106424A2 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
ME00485B (me) * 2005-10-07 2011-10-10 Zoetis Services Llc VAKCINE l METODE LIJEČENJA INFLUENCE KOD CANINA
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
EP1941033A2 (en) * 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions and methods for the treatment of canine influenza virus disease
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US20090304735A1 (en) * 2006-05-19 2009-12-10 Gabrielle Therese Belz Immunogenic Compositions

Also Published As

Publication number Publication date
AU2017203244B2 (en) 2019-05-09
PH12013501598B1 (en) 2018-08-17
CA2826060A1 (en) 2012-08-09
DK2670432T3 (da) 2021-04-19
ZA201306615B (en) 2015-04-29
CY1124093T1 (el) 2022-05-27
MX347177B (es) 2017-04-17
JP2014504635A (ja) 2014-02-24
BR112013019675B8 (pt) 2022-11-22
WO2012104821A1 (en) 2012-08-09
RU2554480C2 (ru) 2015-06-27
BR112013019675B1 (pt) 2021-06-22
UA110504C2 (ru) 2016-01-12
AU2012213035A1 (en) 2013-08-15
PH12013501598A1 (en) 2013-09-30
PT2670432T (pt) 2021-05-04
SI2670432T1 (sl) 2021-08-31
PL2670432T3 (pl) 2021-10-11
NZ613759A (en) 2015-09-25
JP5833145B2 (ja) 2015-12-16
US20130302369A1 (en) 2013-11-14
RS61723B1 (sr) 2021-05-31
KR101647180B1 (ko) 2016-08-09
ES2869175T3 (es) 2021-10-25
EP3858381A1 (en) 2021-08-04
SMT202100233T1 (it) 2021-05-07
MX2013009012A (es) 2013-12-06
EP2670432A1 (en) 2013-12-11
HUE055669T2 (hu) 2021-12-28
CN107296955B (zh) 2021-11-23
HK1245676A1 (zh) 2018-08-31
BR112013019675A2 (pt) 2017-01-31
EP2670432B1 (en) 2021-03-17
KR20130118975A (ko) 2013-10-30
HRP20210575T1 (hr) 2021-05-28
AU2017203244A1 (en) 2017-06-08
CN107296955A (zh) 2017-10-27
CN103561763A (zh) 2014-02-05
CO6791568A2 (es) 2013-11-14
CA2826060C (en) 2019-06-18
LT2670432T (lt) 2021-05-25
CL2013002219A1 (es) 2014-01-31
RU2013136151A (ru) 2015-03-10

Similar Documents

Publication Publication Date Title
UA110505C2 (ru) Імуногенні композиції bordetella bronchiseptica
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
CO6491048A2 (es) Inhibidores de la replicación de los virus de la gripe
UA117095C2 (uk) Нуклеозидна сполука або її фармацевтично прийнятна сіль
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
CO6831973A2 (es) Composición inmunogénica para modulación del sistema inmune y su uso, método de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
EA201491889A1 (ru) Соединения и способы для противовирусной терапии
EP2985288A4 (en) PIGS PSEUDORABIESVIRUS, VACCINE COMPOSITION, AND METHOD OF PREPARATION AND USE THEREOF
UY32274A (es) Pestivirus quimericos
CL2008003845A1 (es) Vacuna que comprende una emulsion, una bacterina tratada termicamente a 55-70°c por 5-10 horas, que comprende una suspension de bacterias muertas de la especie leptospira bratislava, y de 1 a 13 virus causantes de enfermedad porcina.
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
CL2016000300A1 (es) Métodos terapéuticos
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
BR112013019850A8 (pt) Composições de vacina e seu uso no tratamento ou prevenção de doenças respiratórias infecciosas caninas
CL2012003737A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterologo derivado de un virus del moquillo canino; procedimiento para preparar dicho virus; composicion inmunogénica que comprende dicho virus; uso de dicho virus para tratar animal contra enfermedad del moquillo canino.
BR112012033121A2 (pt) métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
EA201401202A1 (ru) ВАКЦИНАЦИЯ РЕСПИРАТОРНЫМ КОРОНАВИРУСОМ СОБАК ДЛЯ ЗАЩИТЫ ОТ ИНФЕКЦИЙ B.Bronchiseptica
MX385188B (es) Vacuna de rinitis equina.
MX2016000021A (es) Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn.
MX2014009022A (es) Virus de influenza c y vacuna.
BR112015003074A2 (pt) composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido etilenodiaminatetra-acético.